SENTINEL UIBC LIQUID

K051111 · Sentinel Ch. Srl · JQF · Nov 17, 2005 · Clinical Chemistry

Device Facts

Record IDK051111
Device NameSENTINEL UIBC LIQUID
ApplicantSentinel Ch. Srl
Product CodeJQF · Clinical Chemistry
Decision DateNov 17, 2005
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 862.1415
Device ClassClass 1

Intended Use

The Sentinel UIBC Liquid (Unsaturated Iron Binding Capacity) assay is intended to measure the unsaturated iron-binding capacity in serum and plasma. Iron-binding capacity measurements are used in the diagnosis and treatment of anemia. For prescription use only.

Device Story

Sentinel UIBC Liquid is a quantitative spectrophotometric reagent pack for use on Abbott AEROSET and ARCHITECT c8000 analyzers. The system measures unsaturated iron-binding capacity (UIBC) in human serum or plasma. The assay saturates transferrin with a known excess of iron in an alkaline buffer; remaining free iron is reduced and complexed by the chromophore Ferene-S. The analyzer measures the decrease in free iron concentration spectrophotometrically. Used by laboratory professionals in clinical settings. Output is a UIBC value (µg/dL), which clinicians use to assess iron status and manage anemia.

Clinical Evidence

Bench testing only. Precision studies showed intra-assay imprecision <3% and inter-assay imprecision 4-9.6%. Linearity was established over the assay range with recovery within 4% of expected values. Analytical specificity testing showed no interference from hemoglobin (up to 200 mg/dL), bilirubin (up to 50 mg/dL), or triglycerides (up to 1000 mg/dL). Method comparison against the predicate device using 59-60 clinical samples showed high correlation (R=0.999 on Architect; R=0.9144 on Aeroset).

Technological Characteristics

Quantitative spectrophotometric assay. Reagents: Tris buffer (pH 8.6), Ferene-S chromophore (22.0 mM), and iron standard (90 µM Fe+3). Calibration traceable to NIST SRM 3126a. Designed for automated use on Abbott AEROSET and ARCHITECT c8000 analyzers. Standards referenced: CLSI EP05-A2 (precision) and CLSI EP06-A (linearity).

Indications for Use

Indicated for patients requiring measurement of unsaturated iron-binding capacity in serum and plasma to assist in the diagnosis and treatment of anemia.

Regulatory Classification

Identification

An iron-binding capacity test system is a device intended to measure iron-binding capacity in serum. Iron-binding capacity measurements are used in the diagnosis and treatment of anemia.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the words "SENTINEL DIAGNOSTICS" stacked on top of each other. The word "SENTINEL" is in a larger, bold font, while the word "DIAGNOSTICS" is in a smaller font. The text is black and the background is white. NOV 1 7 2005 # 510k Summary Sentinel UIBC Liquid KOSIIII K Number:___ - 1. Submitter's information: Mr. Ugo De Luca Managing Director Sentinel CH Srl Via Principe Eugenio 20155 Milan, Italy Tel.: +39 02 345514 1 Fax: +39 02 345514 64 e-mail: sentinel@sentinel.it - 2. Contact person: Mr. Davide Spada International Product Specialist Sentinel CH Srl Via Principe Eugenio 20155 Milan, Italy Tel.: +39 02 345514 1 Fax: +39 02 345514 64 e-mail: spada@sentinel.it - 3. Date summary prepared: 10 November 2005 ### 4. Device name and classification The Sentinel UIBC Liquid described in this 510(k) consists of reagents and standard, packaged and distributed in one kit. The device is intended to be sold as an in-vitro test for professional use. {1}------------------------------------------------ Image /page/1/Picture/0 description: The image shows the word "SENTINEL" in bold, black letters. Below the word, there is a series of small dots that appear to be a stylized design element. The font is sans-serif and the overall impression is clean and modern. Product name and classification information are provided in Table 4.1 below. | Trade/Device Name | Regulation Number | Regulation name | Classification panel | Regulatory class | Product Code | |----------------------|--------------------|-----------------|-----------------------|------------------|--------------| | Sentinel UIBC Liquid | 21 CFR<br>862.1415 | UIBC | Clinical<br>Chemistry | I | JMO | Device names and classification of Sentinel UIBC I iguid Tahlo 4 1 #### 5. Device description The Sentinel UIBC Liquid described in this 510(k) submission is composed of reagents and standard, packaged and distributed in the same kit. The device is intended to be sold as an in vitro test for professional use. Serum is added to an alkaline buffer/reductant solution containing a known concentration of iron to saturate the available binding sites on transferrin. The iron that remains free after transferrin saturation is reduced to a ferrous state and then complexed by Ferene-S to form a stable complex, of which the color intensity is measured at 580-600nm. UIBC is therefore determined by subtracting the quantity of unbound iron from the total added quantity. #### 6. Intended Use The Sentinel UIBC Liquid (Unsaturated Iron Binding Capacity) assay is intended to measure the unsaturated iron-binding capacity in serum. Iron-binding capacity measurements are used in the diagnosis and treatment of anemia. CFR 862.1415 #### Comparison with Predicate Devices 7. Table 7, 1 lists the predicate device for the Sentinel product included in this submission, and provides information on the regulatory status of the predicate device, including the 510(k) number. | Sentinel Trade<br>Device Name | Predicate Device<br>Name | Predicate Device<br>Manufacturer | Predicate<br>device (k) | FDA clear-<br>ance date | |-------------------------------|--------------------------|----------------------------------|-------------------------|-------------------------| | Sentinel UIBC<br>Liquid | Roche UIBC | Roche | K770748* | 06/01/1977 | Table 7.1 Predicate device for Sentinel UIBC Liquid * The Roche UIBC - Predicate Device – was cleared via Hycel, INC. (K0770748). Roche aquired Hycel on June 8, 1979. Table 7.2 below report a comparison of the Sentinel UIBC Liquid with the Predicate Device Roche UIBC. No substantial differences can be noted. The two devices are intended to be used on Automatic Analyzers: the predicate device with the Roche/Hitachi analyzers, the Sentinel UIBC Liquid on the Abbott AEROSET and ARCHITECT analyzers. {2}------------------------------------------------ Image /page/2/Picture/0 description: The image shows the word "SENTINEL" in bold, black letters. The letters are large and spaced closely together. Below the word, there is a faint, dotted line that runs the length of the word. The background is white. | | Design Feature & | | | | |---|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--| | 1 | Sample Type | Human serum and plasma<br>(only heparin salts) | Same | | | 2 | Principle | • Transferrin saturation with<br>a known iron amount;<br>· quantitation of Free iron;<br>· UIBC determined by<br>subtracting the quantity of<br>unbound iron from the total<br>added quantity | Same | | | 3 | Chromogen | Ferene-S | FerroZine | | | | Calibration | Against aqueous standard | Same | | | | Linearity | up to 500 µg/dL | Same | | | 6 | Reference Range | 110-370 µg/dL | Same | | | | Instrumentation | Abbott AEROSET and<br>Abbott ARCHITECT c8000<br>analyzers | Roche / Hitachi Automatic<br>Analyzers | | ## Table 7.2 Comparison with Predicate Device #### Performance Data 8. Performance evaluations included sensitivity, intra- and inter-assay precision, linearity and method comparison. In the method comparison study evaluating 60 serum samples, the correlation (r, y=mx+q)) of the Sentinel UIBC Liquid on the Abbott AEROSET to the predicate device Roche UIBC was 0.9144, y=1.024x + 14.64. #### 9. Conclusion The performance and safety data presented in this premarket notification support a finding of substantial equivalence between the Sentinel UIBC Liquid and the predicate devices specified in this submission. {3}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the seal of the Department of Health & Human Services (USA). The seal features a stylized eagle with its wings spread, symbolizing protection and service. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES, USA" are arranged in a circular pattern around the eagle. Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 NOV 1 7 2005 Mr. Davide Spada Application Specialist Sentinel CH Srl Via Principe Eugenio, 5 20155 Milan, Italy Re: k051111 Trade/Device Name: Sentinel UIBC Liquid Regulation Number: 21 CFR 862.1415 Regulation Name: Iron-binding capacity test system Regulatory Class: Class I Product Code: JOF Dated: October 18, 2005 Received: November 8, 2005 Dear Mr. Spada: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {4}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Alberto Gutierrez, Ph.D. Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ 510(k) Number (if known): _ K05 ll | / Device Name: _________________________________________________________________________________________________________________________________________________________________ Sentinel UIBC Liquid Indications For Use: ﺮ ﻋﻤﺮﺍ The Sentinel UIBC Liquid (Unsaturated Iron Binding Capacity) assay is intended to measure the unsaturated iron-binding capacity in serum and plasma. Iron-binding capacity measurements are used in the diagnosis and treatment of anemia. CFR 862.1415 Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Division Sign-Off Office of In Vitro Diggnostic Device Evaluation and Safety 510(k) K052111 Page 1 of_1___________________________________________________________________________________________________________________________________________________________________
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...